(NASDAQ: LGVN) Longeveron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 21.15%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 68.19%.
Longeveron's earnings in 2026 is -$22,704,000.On average, 4 Wall Street analysts forecast LGVN's earnings for 2026 to be -$14,595,862, with the lowest LGVN earnings forecast at -$18,925,991, and the highest LGVN earnings forecast at -$9,772,457. On average, 4 Wall Street analysts forecast LGVN's earnings for 2027 to be -$14,714,528, with the lowest LGVN earnings forecast at -$20,522,159, and the highest LGVN earnings forecast at -$8,306,588.
In 2028, LGVN is forecast to generate -$20,410,474 in earnings, with the lowest earnings forecast at -$19,610,063 and the highest earnings forecast at -$21,010,782.